Türkiye Parazitoloji Dergisi (Jun 2023)

Retrospective Analysis of Serology and Radiology Results in Patients with Suspected Cystic Echinococcosis Through 3 Years Period

  • Büşra Betül Özmen Çapın,
  • Barış Can,
  • Meltem Kurşun,
  • Canan Cimşit,
  • Ayşegül Karahasan

DOI
https://doi.org/10.4274/tpd.galenos.2023.24186
Journal volume & issue
Vol. 47, no. 2
pp. 83 – 87

Abstract

Read online

Objective:Cystic echinococcosis (CE), caused by the larval stage of Echinococcus granulosus sensu latu, is one of the neglected zoonotic infectious diseases and Türkiye is among the endemic countries. This study was designed to analyze serology results for patients who were diagnosed as CE by clinical symptoms and radiological methods over a three-year period.Methods:Sera were analyzed for Anti-E. granulosus IgG by a chemiluminescence immunoassay (CLIA) (HYDATIDOSIS VIRCLIA® IgG MONOTEST, Vircell) using the VIRCLIA® (CLIA; Vircell, Granada, Spain) and results processed by the dedicated software. Cut-off for a positive test was ≥1.1 index value. Echinococcal cysts were detected based on ultrasonography, computed tomography, and magnetic resonance imaging.Results:A total of 244 sera were analyzed from 109 patients, during three-year-period from January 2018 to December 2020. Anti-E. granulosus IgG was ordered twice in 89 patients, three times in 15 patients, four times in four patients, and five times in one patient. CLIA test was positive among 41 of 109 (37.6%) patients in whom 32 (76%) had only hepatic involvement, whereas in 5 (12%) hepatic and pulmonary involvement were coexisted. The mean age of seropositive patients was 39.8 (6-75±2.72) and 61.9% of them (n=26) were female. Time intervals between sequential test orders varied from 1 day to 33 months. Eight seropositive patients turned out to be negative, and one of 66 seronegative patients became seropositive. Positive test results were converted to negative in the case of therapy or cyst inactivity.Conclusion:We may conclude that CLIA could be used as a complementary tool for CE patient follow-up.

Keywords